A Study of the Efficacy and Safety of Tocilizumab for Confirmed Rheumatoid Arthritis (RA) Participants in Clinical Practice
NCT02616328 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 8
Last updated 2018-10-18
Summary
This is a single-arm, open-label, non-randomized, multicenter trial to evaluate the efficacy and safety of using tocilizumab for confirmed rheumatoid arthritis participants in clinical practice.
Conditions
Interventions
- OTHER
-
No intervention
No intervention administered in this study
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Clinical Trials · Hoffmann-La Roche
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-01-26
- Primary Completion
- 2017-12-12
- Completion
- 2017-12-12
Countries
- Saudi Arabia
Study Locations
More Related Trials
-
Use of Tocilizumab for Rheumatoid Arthritis (RA) in Daily Routine
NCT02809833 ·Status: COMPLETED
-
Uncontrolled Study to Evaluate Efficacy of Tocilizumab in Patients With Moderate or Severe Rheumatoid Arthritis
NCT02087696 ·Status: UNKNOWN ·Phase: PHASE4
-
To Evaluate 1 Year Extension Study of the Efficacy and Safety of Tocilizumab in Patients With Moderate to Severe Rheumatoid Arthritis
NCT01256736 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of the Effect of Tocilizumab on Markers of Atherogenic Risk in Patients With Moderate to Severe Rheumatoid Arthritis
NCT00535782 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to DMARDs or Anti-TNF
NCT01326962 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis
NCT01211834 ·Status: COMPLETED ·Phase: PHASE3
-
A Long-Term Extension Study to WA19926 (NCT01007435) of Tocilizumab in Participants With Early, Moderate to Severe Rheumatoid Arthritis
NCT01665430 ·Status: TERMINATED ·Phase: PHASE3
-
A Study of Tocilizumab Added to DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to DMARDs.
NCT00996203 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Understand How Effective is Tofacitinib When Compared to Other Advanced Treatments in Patients With Rheumatoid Arthritis
NCT06418529 ·Status: COMPLETED
-
A Study to Assess the Effect of Tocilizumab on Signs and Symptoms in Patients With Rheumatoid Arthritis
NCT00848120 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Tocilizumab as Monotherapy or in Combination With DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis
NCT01089023 ·Status: COMPLETED ·Phase: PHASE4
-
A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic Disease-modifying Antirheumatic Drugs (DMARDs)
NCT00891020 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Assess the Effect of Tocilizumab + DMARD Therapy on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis
NCT00106574 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Tocilizumab (RoActemra) in Tocilizumab-Naive Participants With Rheumatoid Arthritis and Inadequate Response to Non-Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) and/or Biologic Therapy
NCT02001987 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of RoActemra/Actemra (Tocilizumab) in Combination With DMARDs Versus Current Best Practice DMARD Therapy in Patients With Rheumatoid Arthritis
NCT01251120 ·Status: TERMINATED ·Phase: PHASE4
-
A Study to Assess the Effect of Tocilizumab + Methotrexate on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis
NCT00106548 ·Status: COMPLETED ·Phase: PHASE3
-
An Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis
NCT01277328 ·Status: TERMINATED
-
An Exploratory Study of Tocilizumab in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Current Non-Biologic DMARDs and/or Anti-TNF Therapy.
NCT00750880 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Tocilizumab in Patients With Rheumatoid Arthritis
NCT01187563 ·Status: COMPLETED
-
An Efficacy and Safety Study of Subcutaneous Tocilizumab in Combination With Methotrexate (MTX) and as Monotherapy Versus MTX in Participants With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Current Disease-Modifying Antirheumatic Drug (DMARD) Therapy
NCT03155347 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Tocilizumab in Participants With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Non-Biological Disease-modifying Anti-rheumatic Drugs (DMARDs)
NCT01617005 ·Status: COMPLETED
-
A Study of the Efficacy and Safety of Tocilizumab in Adults With Rheumatoid Arthritis.
NCT01988012 ·Status: COMPLETED ·Phase: PHASE3
-
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
NCT02097524 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess the Safety and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis
NCT00109408 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Assess the Effect of Tocilizumab + Methotrexate on Prevention of Structural Joint Damage in Patients With Moderate to Severe Active Rheumatoid Arthritis (RA)
NCT00106535 ·Status: COMPLETED ·Phase: PHASE3